Cancer Biology

1237 A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.

1236 Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

1235 METTL14 facilitates global genome repair and suppresses skin tumorigenesis.

1234 Cycling cancer persister cells arise from lineages with distinct programs.

1233 A new computational approach to in silico mutagenesis screening allow comprehensive mapping of cancer driver mutations.

1232 Drivers and suppressors of triple-negative breast cancer.

1231 Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

1230 UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.

1229 EGFR activation limits the response of liver cancer to lenvatinib.

1228 A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice.

1227 Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.

1226 Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.

1225 Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.

1224 Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment.

1223 A nanovaccine based on bacterial cytoplasmic membranes and cell membranes from resected tumor tissue prevents tumor recurrence in mice.

1222 Down-regulation of A20 promotes immune escape of lung adenocarcinomas.

1221 Initiation and progression of leukemogenesis in Down syndrome involves distinct cellular origins and effects of trisomy 21.

1220 Li et al. identify LIMIT as a lncRNA that modulates MHC-I expression through HSP90 and HSF1, thereby regulating antitumour immune response and the efficacy of immunotherapy.

1219 AI-based pathology predicts origins for cancers of unknown primary.

1218 Treatment with a specific inhibitor of the N6-methyladenosine methyltransferase METTL3 leads to reduced growth of cancer cells, indicating the potential of approaches targeting RNA-modifying enzymes for anticancer therapy.

Free Images for Presentation: sunipix SUNIPIX